March 25 (Reuters) - AbbVie said on Monday it would acquire drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
Nancy Pelosi's husband Paul Pelosi uses an investing strategy that lowers upfront costs.
The $50 million purchase could turn into Nvidia's biggest investment.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
AI could generate trillions of dollars over the next ten years. One company is already an early winner of this windfall.
The tobacco giant will soon be allowed to sell a proven product in a proven market.
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
The bank CEO says the company looks for candidates who are “smart, ethical, decent people.”